⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6536476 | 0.75 | MEN1 (0.31) | — | |
| SCHEMBL6681441 | 0.73 | — | — | |
| SCHEMBL4741585 | 0.72 | ALDH1A1 (0.35) | — | |
| SCHEMBL9662746 | 0.71 | GDA (0.30) | — | |
| SCHEMBL20975019 | 0.71 | — | — | |
| SCHEMBL20589944 | 0.71 | — | — | |
| SCHEMBL5958156 | 0.69 | ABL1 (0.34) | — | |
| SCHEMBL13735762 | 0.54 | ALDH1A1 (0.65) | — | |
| SCHEMBL4874802 | 0.53 | CYP1A2 (0.30) | — | |
| SCHEMBL13735766 | 0.52 | ALDH1A1 (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381694-A4 | METHODS FOR IDENTIFYING LIGAND BINDING SITES IN A BIOMOLECULE | ISIS PHARMACEUTICALS INC (US) | 2006-08-16 | — | — | EP | claimed |
| US-6730484-B2 | POLYNUCLEOTIDE OR POLYPEPTIDE, AS WELL AS METHODS FOR DETERMINING WHETHER A PARTICULAR SITE IN A TARGET MOLECULE IS AT OR NEAR THE LIGAND BINDING SITE, ARE PROVIDED. LIGAND BINDING AFFINITIES CORRESPONDING TO BOTH THE TARGET MOLECULE | ISIS PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | claimed |
| US-6730485-B2 | DETECTION OF BINDING DOMAIN IN POLYPEPTIDE; OBTAIN POLYPEPTIDE, INCUBATE WITH LIGAND, EXPOSE SPECTRUM ANALYSIS, DETECT BINDING DOMAIN IN PROTEIN | ISIS PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | claimed |
| EP-1381694-A1 | METHODS FOR IDENTIFYING LIGAND BINDING SITES IN A BIOMOLECULE | ISIS Pharmaceuticals, Inc. (US) | 2004-01-21 | — | — | EP | claimed |
| US-6653067-B1 | Contacting with modified/unmodified test molecule and dissociating; comparing the unseparated complexes; mass spectrometry; use in drug discovery | ISIS PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | claimed |
| US-20030165915-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | claimed |
| US-20030077630-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-04-24 | — | — | US | claimed |
| US-20030013113-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| WO-2002068691-A1 | METHODS FOR IDENTIFYING LIGAND BINDING SITES IN A BIOMOLECULE | ISIS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | claimed |
| EP-4740951-A2 | IGH REARRANGEMENTS AND USES THEREOF | Foundation Medicine, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4267767-B1 | IGH REARRANGEMENTS AND USES THEREOF | FOUND MEDICINE INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260069717-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250378926-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-6730484-B2 | POLYNUCLEOTIDE OR POLYPEPTIDE, AS WELL AS METHODS FOR DETERMINING WHETHER A PARTICULAR SITE IN A TARGET MOLECULE IS AT OR NEAR THE LIGAND BINDING SITE, ARE PROVIDED. LIGAND BINDING AFFINITIES CORRESPONDING TO BOTH THE TARGET MOLECULE | ISIS PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-6730485-B2 | DETECTION OF BINDING DOMAIN IN POLYPEPTIDE; OBTAIN POLYPEPTIDE, INCUBATE WITH LIGAND, EXPOSE SPECTRUM ANALYSIS, DETECT BINDING DOMAIN IN PROTEIN | ISIS PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-6653067-B1 | Contacting with modified/unmodified test molecule and dissociating; comparing the unseparated complexes; mass spectrometry; use in drug discovery | ISIS PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030165915-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
| US-20030077630-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-04-24 | — | — | US | disclosed |
| US-20030013113-A1 | Methods for identifying ligand binding sites in a biomolecule | ISIS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |